Page 289 - bandung_Neat

The candidate vaccine known as CoronaVac and previously PiCoVacc, is among
few potential vaccines that have entered late-stage trials for a large-scale study to
gather proof of efficacy for regulatory approval.

It is one of 26 candidate vaccines that are in clinical evaluation according to a
compilation made by the World Health Organization (WHO) on July 31. There are
139 candidate vaccines in preclinical evaluation.

If the clinical trial proves the candidate vaccine is effective in battling the coronavirus,
the minister vowed to facilitate the company for mass production.

“I thank the volunteers, the laboratory teams from Bio Farma and Sinovac, as well as
Padjadjaran University for conducting the crucial stage of this vaccine development.
[…] If it goes well, we will prepare the vaccine registration to the Food and Drug
Supervisory Agency (BPOM), so that the vaccine can be massively produced to
combat COVID-19,” he added.

Previously, Erick claimed Bio Farma was ready to produce 250 million doses of the
Sinovac coronavirus vaccine per year by the end of 2020.

Fourteen days after receiving the first injections, volunteers who show no reaction
will be scheduled to receive the second injection and the health condition of each
volunteer will be followed over the course of six months. The clinical trials are
expected to be finished by January 2021 at the earliest.